• About us
• Contact

Advertisement

Organisation › Details

Advent France Biotechnology Seed-Fund I (AFB Seed Fund I)

Advent France Biotechnology (AFB), an AMF-regulated company created in 2016 in Paris, France, invests in a range of sectors within the life sciences, specifically in drug discovery and new medical technologies. AFB has made 12 investments since the inception of its first fund in 2017, mainly in France but also in Belgium and Spain. It has selected well differentiated projects across diverse therapeutics areas: oncology, inflammation, neurology, infectious diseases, metabolic disorders, rare diseases, enabling technologies and e-health. It has developed strong relationships within the French innovation ecosystem and attracted international VC syndicates into its portfolio companies. The operational team, managed by Alain Huriez and Matthieu Coutet, includes investment professionals with extensive scientific, medical and operational experience, as well as a long-standing track record of entrepreneurial and investment successes across Europe. *

 

	Start	2017-04-20 closing, first
	Group	AdBio Partners (Group)
	Industry	Advent France Biotechnology Seed-Fund I (AFB Seed Fund I)
	Industry 2	BIOTECH
	Region	Paris
	Country	France
	Street	4 rue Thénard
	City	75005 Paris
	Tel	+33-1-5681-6300
		Address record changed: 2021-12-08
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	64,750,000 (fund size at first closing (2017) 2017-04-20)
		* Document for »About Section«: Advent France Biotechnology SAS. (10/6/20). "Press Release: Advent France Biotechnology Appoints Geoffroy de Ribains as Operating Partner". Paris.
		Record changed: 2024-02-12

Advertisement

More documents for AdBio Partners (Group)

• [1] Astraveus SAS. (6/27/23). "Press Release: Astraveus Raises €16.5 Million Series Seed Round to Advance the Development of Its Automated, Microfluidic Cell and Gene Therapy Manufacturing Platform". Paris....
• [2] Calida Therapeutics SAS. (4/6/23). "Press Release: French Biotech Calida Therapeutics Launches with Seed Funding, Leveraging US Academic Research in Thrombo-inflammatory Disorders". Paris....
• [3] AdBio Partners SAS. (2/23/23). "Press Release: AdBio Partners Appoints Geoffroy de Ribains as Managing Partner". Paris....
• [4] Thabor Therapeutics SAS. (5/17/22). "Press Release: Thabor Therapeutics Appoints Jérémie Mariau as CEO". Paris....
• [5] AdBio Partners SAS. (5/3/22). "Press Release: AdBio Partners Welcomes Inserm Transfert as Investor in Second Fund – AFB Fund II". Paris....
• [6] AdBio Partners SAS. (12/7/21). "Press Release: Advent France Biotechnology Becomes AdBio Partners". Paris....
• [7] Advent France Biotechnology SAS. (9/30/21). "Press Release: Advent France Biotechnology Launches Its Second Fund with a First Close at €86M ($102M)". Paris....
• [8] Aglaia Therapeutics. (9/27/21). "Press Release: New Startup Aglaia Therapeutics Raises €4M in Seed Funding to Overcome Resistance in Oncology Targeted Therapies". Villejuif....
• [9] Advent France Biotechnology SAS. (6/8/21). "Press Release: Advent France Biotechnology Appoints Sidonie Fabre as CFO". Paris....
• [10] Augustine Therapeutics. (3/18/21). "Press Release: Augustine Therapeutics Appoints Sylvain Celanire as CEO to Accelerate Development of Innovative Medicines for Rare Neuromuscular Diseases". Leuven....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.